Reuters Edition: U.S. Change Edition YOU'RE VIEWING: United States US Africa AF Arabic ARA Argentina AR Brazil BR Canada CA China CN France FR Germany

China slashed the maximum retail price for more than 1,200 types of antibiotics and circulatory system drugs on Monday in a move likely to crimp the profits of foreign and local drug makers. The National Development and Reform Commission (NDRC), the country's state planning agency, announced rules earlier this month requiring hospitals and clinics nationwide to cap the price of certain drugs. The rules take effect on Monday. The price caps, which are aimed at combating inflation and warding off disgruntlement over high healthcare costs, will cut the prices of 1,265 types of drugs by an average of 21 percent, according to Pharma China, a publication that specialises in China's pharmaceutical sector. The NDRC estimated that the rules will save patients 10 billion yuan ($1.53 billion) annually. "The impact is definitely negative to the bottom line (of pharmaceutical makers)," said Linus Yip, chief strategist for First Shanghai Securities in Hong Kong. The NDRC also pledged to step up inspection with violators facing fines of up to five times the value of "unlawful" profits or closure. Chinese hospitals are notorious for padding revenues and doctors' salaries by prescribing expensive or unnecessary medication, a practice that infuriates ordinary Chinese. The price cuts will have a bigger impact on smaller Chinese drug makers than the global pharmaceutical companies, who can more easily absorb the impact to their revenues, said Yip. The multinational companies affected by the rules include Pfizer , Novartis , GlaxoSmithKline and Sanofi Aventis , according to industry publication Pharma China. China's leaders have repeatedly said their most important task this year is controlling inflation. So far, complaints about rising prices have amounted to little more than grumbles, but inflation has sparked social unrest in the past. The country's inflation topped expectations at 4.9 percent in the year to February, near its fastest level in more than two years, and looks set to climb in coming months.